Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulindac and polyp regression

F M Giardiello1

  • 1Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287-4461, USA.

Cancer Metastasis Reviews
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Colorectal cancer in ulcerative colitis: survival in patients with and without colorectal cancer symptoms.

Inflammatory bowel diseases·2013
Same author

Mucosal prolapse syndrome presenting as rectal polyposis.

Journal of clinical pathology·2009
Same author

No TGFBRII germline mutations in juvenile polyposis patients without SMAD4 or BMPR1A mutation.

Gut·2008
Same author

Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis.

Gut·2008
Same author

Genetic defects underlying Peutz-Jeghers syndrome (PJS) and exclusion of the polarity-associated MARK/Par1 gene family as potential PJS candidates.

Clinical genetics·2007
Same author

Peutz-Jeghers syndrome polyps are polyclonal with expanded progenitor cell compartment.

Gut·2007
Same journal

HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.

Cancer metastasis reviews·2026
Same journal

Resolving translational challenges in cancer biology through yeast experimental evolution.

Cancer metastasis reviews·2026
Same journal

Spheroids and organoids to study long noncoding RNAs in cancer: how they could replace animal models.

Cancer metastasis reviews·2026
Same journal

Strategies and successes of smoking cessation methods in head and neck cancer patients: a systematic review.

Cancer metastasis reviews·2026
Same journal

The Hippo signaling pathway in pediatric brain tumors: molecular mechanisms and therapeutic opportunities.

Cancer metastasis reviews·2026
Same journal

Antibody-drug conjugates in breast cancer brain and leptomeningeal metastases: mechanistic insights and therapeutic progress.

Cancer metastasis reviews·2026
See all related articles

Sulindac effectively reduces adenomatous polyps, a precursor to colorectal cancer. However, further research is needed to confirm its long-term impact on cancer risk and explore its use in diverse patient groups.

Area of Science:

  • Gastroenterology
  • Oncology
  • Pharmacology

Background:

  • Adenomatous polyps are precursors to colorectal cancer.
  • Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), has shown promise in regressing these polyps.
  • The precise mechanisms and long-term efficacy require further investigation.

Purpose of the Study:

  • To evaluate the efficacy of sulindac in causing regression of adenomatous polyps.
  • To explore the potential of sulindac as a chemopreventative agent for colorectal cancer.
  • To investigate the underlying mechanisms of sulindac's action and its clinical applications.

Main Methods:

  • Review of existing clinical studies and observations on sulindac's use.
  • Comparison with related NSAIDs like indomethacin.

Related Experiment Videos

  • Analysis of sulindac's metabolism and distribution, particularly the active sulfide metabolite.

    • Main Results:

    • Sulindac demonstrated efficacy in causing adenoma regression, both orally and rectally.
    • Indomethacin did not show similar polyp regression effects.
    • Observed recurrence of adenomas after sulindac discontinuation suggests a need for continuous treatment.

    Conclusions:

    • Sulindac is a potential chemopreventative agent for colorectal adenomas.
    • Further studies are essential to confirm its role in reducing colorectal cancer risk in various populations.
    • The exact mechanism of adenoma regression, potentially involving prostaglandin inhibition, warrants deeper exploration.